Tag Archives: biotechnology

Prometheus v. Roxane – A Glimpse of Christmas Future?

Posted on November 16, 2015 by Warren Woessner

A Fed. Cir. panel of Judges Dyk, Taranto and Hughes affirmed the district court’s invalidation of a Prometheus “add-on” patent (U.S. Pat. No. 6,284,770) to a method to treat a form of irritable bowel syndrome, IBS-D, with alosetron, as obvious … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , , , | Leave a comment

Australian Patent Office Proposes “Coding Only” Sequence Ban

Posted on October 22, 2015 by Warren Woessner

Coming soon after the High Court’s “Myriad decision” in Australia, the Australian Patent Office has proposed guidelines that would effectively limit the ban on patent-eligibility of DNA sequences to nucleic acids that code for polypeptides. While cDNA is still considered … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , , , , , , | Leave a comment

Janice Mueller’s New Article: Patent -Ineligible Methods of Treatment

Posted on October 12, 2015 by Warren Woessner

Patent-Ineligible Methods of Treatment Janice M. Mueller  Chisum Patent Academy October 3, 2015 Janice M. Mueller, Patent-Ineligible Methods of Treatment, in MUELLER ON PATENT LAW, VOL. I (PATENTABILITY AND VALIDITY) (Wolters Kluwer Law & Business 2012), last revised October 2015 … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , | 1 Comment

USPTO Report on State of Confirmatory Genetic Testing Comes off the Waffle Iron

Posted on October 12, 2015 by Warren Woessner

In 2011—after the Fed. Cir. decision in Myriad upholding claims to BRACA1 and 2 genes—the PTO was tasked by a section of the AIA with providing Congress with a report on the effect of patenting on confirmatory genetic testing. The … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , , , | Leave a comment